Animal study (in vivo) · rat · 2021
Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats.
Kurkin et al. 2021PloS onecited by 22
PMID 34260655PMC8279368DOI 10.1371/journal.pone.0254493PUB-34260655
PepBank has 97 Cortexin studies with results. 77 of them gave Cortexin, with 252 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 252 results and 168 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Cortexin contains water-soluble polypeptide fractions from animal cerebral cortex. It is not a single sequence-defined peptide. The official manufacturer describes cattle-derived cortical polypeptides. Its current Russian registrations are ЛП-№(000636)-(РГ-RU) and ЛП-№(000620)-(РГ-RU); the earlier Р N003862/02 expired on 2025-09-19. Cortexin differs from Cerebrolysin and the defined tetrapeptide Cortagen.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence not disclosed
Cortexin contains water-soluble polypeptide fractions from animal cerebral cortex. It is not a single sequence-defined peptide. The official manufacturer describes cattle-derived cortical polypeptides. Its current Russian registrations are ЛП-№(000636)-(РГ-RU) and ЛП-№(000620)-(РГ-RU); the earlier Р N003862/02 expired on 2025-09-19. Cortexin differs from Cerebrolysin and the defined tetrapeptide Cortagen.
No formula or molecular weight is listed for Cortexin (cortical polypeptide complex).
No sequence is listed, so nothing can be calculated.
No charge curve
No sequence is listed for this peptide.
No sequence is listed for this peptide.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
97 of 168 studies have results (58%), published 1980 to 2026. Top row: every study. Bottom row: studies with results about Cortexin (cortical polypeptide complex), by class. The rows use different scales.
Studies168 in all, 1980 to 2026
Studies with results97 in all, 1980 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
168 studies match. Retracted studies are left out.
Showing 22 of 168 studiesquery qry_2c82723388424c78e0af52e8
97 studies in all, 6 on this page
Animal study (in vivo) · rat · 2021
Kurkin et al. 2021PloS onecited by 22
PMID 34260655PMC8279368DOI 10.1371/journal.pone.0254493PUB-34260655
Randomized controlled trial · 2018
Fedin et al. 2018Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovan = 189cited by 16
PMID 30335070DOI 10.17116/jnevro201811809135PUB-30335070
Animal study (in vivo) · rat · 2019
Zhang et al. 2019Journal of the neurological sciencescited by 15
PMID 30665068DOI 10.1016/j.jns.2019.01.017PUB-30665068
Non-randomized trial · 2018
Zykov et al. 2018Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovan = 635cited by 10
PMID 29652302DOI 10.17116/jnevro20181183127-31PUB-29652302
Observational study · 2018
Fedin et al. 2018Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovan = 388cited by 7
PMID 29460902DOI 10.17116/jnevro20181181130-36PUB-29460902
Animal study (in vivo) · rat · 2020
Tyurenkov et al. 2020Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovacited by 7
PMID 32929929DOI 10.17116/jnevro202012008183PUB-32929929
50 studies in all, 16 on this page
PubMed tag: none · 2004
Marek et al. 2004Journal of cellular physiologycited by 33
PMID 15389548DOI 10.1002/jcp.20087PUB-15389548
PubMed tag: Meta-Analysis · 2014
Chouraki et al. 2014Molecular psychiatrycited by 31
PMID 24535457PMC4418478DOI 10.1038/mp.2013.185PUB-24535457
PubMed tag: Review · 2015
Gomazkov et al. 2015Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovacited by 24
PMID 26356623DOI 10.17116/jnevro20151158199-104PUB-26356623
PubMed tag: none · 2015
Solovyev et al. 2015International journal of biological macromoleculescited by 18
PMID 25841380DOI 10.1016/j.ijbiomac.2015.03.054PUB-25841380
Indexing hint: Animal study · 1993
2nd et al. 1993Journal of neurochemistrycited by 17
PMID 8336151DOI 10.1111/j.1471-4159.1993.tb02183.xPUB-08336151
PubMed tag: none · 2007
Wang et al. 2007International journal of molecular medicinecited by 17
PMID 17786280DOI 10.3892/ijmm.20.4.501PUB-17786280
PubMed tag: none · 1998
De Jager et al. 1998Genomicscited by 12
PMID 9545640DOI 10.1006/geno.1997.5193PUB-09545640
PubMed tag: none · 2021
Mithani et al. 2021Sleep medicinecited by 11
PMID 33530007DOI 10.1016/j.sleep.2021.01.013PUB-33530007
PubMed tag: none · 2009
Chakraborty et al. 2009Journal of the American Society of Hypertension : JASHcited by 10
PMID 20409952DOI 10.1016/j.jash.2008.11.002PUB-20409952
PubMed tag: none · 2015
Šerý et al. 2015Behavioral and brain functions : BBFcited by 8
PMID 25889058PMC4367835DOI 10.1186/s12993-015-0057-9PUB-25889058
PubMed tag: none · 2017
Nemkova et al. 2017Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovacited by 8
PMID 28399095DOI 10.17116/jnevro20171173140-49PUB-28399095
PubMed tag: Clinical Trial · 2013
Ghosh et al. 2013Clinical laboratorycited by 7
PMID 23865344DOI 10.7754/clin.lab.2012.120633PUB-23865344
PubMed tag: none · 2021
Alsulaimani et al. 2021Cerebral circulation - cognition and behaviorcited by 7
PMID 36324709PMC9616232DOI 10.1016/j.cccb.2021.100012PUB-36324709
PubMed tag: none · 2014
Ghosh et al. 2014Cardiology research and practicecited by 6
PMID 24649391PMC3932286DOI 10.1155/2014/412815PUB-24649391
PubMed tag: Review · 2013
Umnov et al. 2013Advances in gerontology = Uspekhi gerontologiicited by 6
PMID 24738258PUB-24738258
PubMed tag: none · 2019
Kuznik et al. 2019Molekuliarnaia biologiiacited by 6
PMID 31099784DOI 10.1134/s0026898419020095PUB-31099784
These studies name Cortexin (cortical polypeptide complex) but give no result for it (for example, the results concern another peptide in the study).
PubMed tag: Systematic Review · 2023
Ziganshina et al. 2023The Cochrane database of systematic reviewscited by 15
PMID 37818733PMC10565895DOI 10.1002/14651858.cd007026.pub7PUB-37818733
PubMed tag: Multicenter Study · 2022
Putilina et al. 2022Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovacited by 9
PMID 35175707DOI 10.17116/jnevro202212201184PUB-35175707
PubMed tag: Comparative Study · 2004
Anisimov et al. 2004Neuro endocrinology letterscited by 8
PMID 15159690PUB-15159690
Page 1 of 2
Fedin AI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2025
Randomized controlled trial · 4 results
Fedin AI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018
Randomized controlled trial · 6 results
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026
Randomized controlled trial · 11 results
Ukhanova TA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2012
Randomized controlled trial · 3 results
Degtyareva VG · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2025
Randomized controlled trial · 6 results
Khabirov FA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2020
Randomized controlled trial · 5 results
Degtyareva VG · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024
Randomized controlled trial · 3 results
Zavadenko NN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2019
Randomized controlled trial · 5 results
Solov'ev AG · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2010
Randomized controlled trial · 2 results
Kovalchuk VV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2019
Non-randomized trial · 2 results
Zykov VP · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018
Non-randomized trial · 3 results
Mashin VV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2014
Non-randomized trial · 4 results
Aliferova VM · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2014
Non-randomized trial · 4 results
Schastnyy ED · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026
Non-randomized trial · 4 results
Yakovenko MP · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2023
Non-randomized trial · 1 result
Evzel'man MA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2013
Non-randomized trial · 3 results
Ukhanova TA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2011
Non-randomized trial · 1 result
Khavinson VKh · Klinicheskaia meditsina · 1999
Non-randomized trial · 3 results
Skripnik OY · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2020
Non-randomized trial · 6 results
Ukhanova TA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2012
Non-randomized trial · 4 results
Nurguzhaev ES · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2009
Non-randomized trial · 7 results
Zavadenko NN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2020
Non-randomized trial · 10 results
Belskaya GN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2014
Non-randomized trial · 4 results
Belova LA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018
Non-randomized trial · 3 results
Skoromets AA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2008
Non-randomized trial · 2 results
Chutko LS · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2021
Non-randomized trial · 5 results
Mashin VV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2019
Non-randomized trial · 4 results
Chutko LS · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2011
Non-randomized trial · 1 result
Trofimova SV · Advances in gerontology = Uspekhi gerontologii · 2008
Non-randomized trial · 1 result
Melnik EA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024
Non-randomized trial · 4 results
Chutko LS · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2019
Non-randomized trial · 1 result
Gafurov BG · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2010
Non-randomized trial · 1 result
Skorokhodov AP · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2006
Non-randomized trial · 6 results
Lysov AV · Problemy tuberkuleza i boleznei legkikh · 2006
Non-randomized trial · 1 result
Chutko LS · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026
Non-randomized trial · 2 results
Belova LA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2016
Non-randomized trial · 2 results
Dambinova SA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2017
Non-randomized trial · 1 result
Belova LA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2016
Non-randomized trial · 2 results
Balakireva EA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2021
Non-randomized trial · 4 results
Rodionova EY · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2017
Non-randomized trial · 1 result
Belova LA · Klinicheskaia meditsina · 2016
Non-randomized trial · 2 results
Nazarova GA · Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury · 2013
Non-randomized trial · 1 result
Shabanov PD · Eksperimental'naia i klinicheskaia farmakologiia · 2007
Non-randomized trial · 4 results
Fedin AI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018
Observational study · 4 results
Putilina MV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024
Observational study · 4 results
Shchepankevich LA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024
Observational study · 4 results
Zhang L · Journal of the neurological sciences · 2019
Animal study (in vivo) · rat · 8 results
Ponomarev GV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2017
Animal study (in vivo) · rat · 4 results
Shchulkin AV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026
Animal study (in vivo) · rat · 11 results
Kurkin DV · PloS one · 2021
Animal study (in vivo) · rat · 15 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | No US medicinal approval was established from the reviewed sources. | 22 Oct 2026 | Not recorded |
| EU | EMA | No central or national medicinal approval was established from the reviewed sources. | 22 Oct 2026 | Not recorded |
| Sport | WADA | Status unknown The 2026 list does not name Cortexin. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | National register | Approved in Russia Registered medicine Cortexin (Кортексин), holder GEROPHARM: registrations ЛП-№(000636)-(РГ-RU) of 2022-03-24 (10 mg) and ЛП-№(000620)-(РГ-RU) of 2022-03-09 (5 mg). The earlier registration Р N003862/02 expired on 2025-09-19. Read from a copy of the State Register of Medicines (pharmcontrol.ru, register data of 2026-10-02); the official register search was not read. | 22 Oct 2026 | pharmcontrol.ru (opens in a new tab) |
18 safety results for Cortexin (cortical polypeptide complex).
In acute ischemic stroke, adverse events totalled 74 (in 60 patients) with initial intravenous Cortexin and 51 (in 41 patients) with intramuscular Cortexin, without a significant between-group difference.
Randomized controlled trialn = 490
1 more measurement in the study.
In patients with neurological complications of diabetes, three adverse events occurred with adjunctive Cortexin and two with comprehensive treatment alone; none were therapy-related.
Randomized controlled trialn = 110
In patients with chronic cerebral ischemia, the study reported safety and good tolerability of cortexin without event counts.
Randomized controlled trialn not reported
In patients with alcohol disorders or polyneuropathy, cortexin was well tolerated without observed side effects.
Randomized controlled trialn not reported
In children with cognitive dysfunction, Cortexin had reported good tolerability without event counts.
Non-randomized trialn = 635
In patients with depressive disorder, adjunctive Cortexin reduced UKU-assessed adverse events more than basic antidepressant treatment alone.
Non-randomized trialn = 98
No adverse events occurred in the Cortexin group with post-Covid cognitive impairment.
Non-randomized trialn = 52
In patients with dyscirculatory encephalopathy, cortexin was well tolerated with no side effects reported.
Non-randomized trialn = 45
In intact infant rats, cortexin caused appreciable disturbances of vagosympathetic balance.
Animal study (in vivo)rat
In intact infant rats, cortexin caused appreciable heart rhythm disturbances.
Animal study (in vivo)rat
In intact infant rats, cortexin disturbed respiration rhythm to a lesser extent than vagosympathetic balance and heart rhythm.
Animal study (in vivo)rat
In cultured MT-4 T-lymphocytes, Cortexin produced cytotoxic effects at certain concentrations.
In vitro (cells)
The doses that these studies used. They are not recommendations.
10 mg twice dailyHuman
10 mg or 20 mgHuman
10 mgHuman
10 mgHuman
10 mg dailyHuman
10 mg/dHuman
6 of 47 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ cortexinEvidence summary for Cortexin (cortical polypeptide complex): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Cognition and memoryNervous system and cognition | Human: 43 results from 20 studies: 32 increase, 7 decrease, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial | Animal: 5 results from 3 studies: 2 increase, 2 decrease, 1 no significant change. Strongest design: Animal study (in vivo) | No results | No results | 48 |
| NeuroprotectionNervous system and cognition | Human: 33 results from 20 studies: 14 increase, 15 decrease, 4 not reported. Strongest design: Randomized controlled trial | Animal: 50 results from 13 studies: 14 increase, 17 decrease, 14 no significant change, 5 not reported. Strongest design: Animal study (in vivo) | Lab: 9 results from 4 studies: 6 increase, 3 decrease. Strongest design: Ex vivo tissue | No results | 92 |
| Adverse eventsWhole body | Human: 15 results from 15 studies: 1 increase, 1 decrease, 1 no significant change, 12 not reported. Strongest design: Randomized controlled trial | Animal: 3 results from 1 study: 3 increase. Strongest design: Animal study (in vivo) | Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cells) | No results | 19 |
| Anxiety and moodMental health and mood | Human: 10 results from 6 studies: 2 increase, 5 decrease, 3 no significant change. Strongest design: Randomized controlled trial | Animal: 4 results from 2 studies: 1 increase, 3 decrease. Strongest design: Animal study (in vivo) | No results | No results | 14 |
| Exercise and physical functionNervous system and cognition | Human: 8 results from 6 studies: 3 increase, 1 decrease, 1 no significant change, 3 not reported. Strongest design: Randomized controlled trial | Animal: 4 results from 2 studies: 3 increase, 1 decrease. Strongest design: Animal study (in vivo) | No results | No results | 12 |
| Inflammation markersNervous system and cognition | Human: 6 results from 1 study: 4 decrease, 2 not reported. Strongest design: Randomized controlled trial | Animal: 5 results from 3 studies: 4 decrease, 1 not reported. Strongest design: Animal study (in vivo) | No results | No results | 11 |
| Overall treatment effectWhole body | Human: 5 results from 4 studies: 1 increase, 2 decrease, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 5 |
| Quality of lifeWhole body | Human: 4 results from 3 studies: 4 increase. Strongest design: Non-randomized trial | No results | No results | No results | 4 |
| PainNervous system and cognition | Human: 3 results from 1 study: 3 decrease. Strongest design: Randomized controlled trial | No results | No results | No results | 3 |
| Oxidative stressNervous system and cognition | Human: 2 results from 1 study: 2 not reported. Strongest design: Randomized controlled trial | Animal: 3 results from 1 study: 2 increase, 1 decrease. Strongest design: Animal study (in vivo) | No results | No results | 5 |
| SeizuresNervous system and cognition | Human: 2 results from 1 study: 1 decrease, 1 not reported. Strongest design: Non-randomized trial | No results | No results | No results | 2 |
| Vision and retinaEye | Human: 2 results from 2 studies: 2 increase. Strongest design: Non-randomized trial | No results | No results | No results | 2 |
12 outcome groups shown of 23 · 252 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.